Evaluation of the use of Proluton-Depot (hydroxyprogesterone hexanoate) in early pregnancy

Varma TR, Morsman J

doi:10.1016/0020-7292(82)90039-x

International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics, 20(1), 13-17, 1982

Evaluation of the use of Proluton-Depot (hydroxyprogesterone hexanoate) in early pregnancy

T R Varma , J. M. Morsman

Author affiliations (2)

St. George's Hospital and Medical School, London, England.
St George's Hospital ROR

DOI10.1016/0020-7292(82)90039-x PMID6126401

Read at publisher

Abstract

This study evaluates the effect of treatment with Proluton-Depot (hydroxyprogesterone hexanoate) in early pregnancy, and the final outcome of pregnancy and fetal status. One hundred and fifty patients received intramuscular injection of Proluton-Depot from 6 weeks to 8 weeks to 16 weeks to 18 weeks gestation. The outcome of this treated group was compared with a similar number of 150 patients with similar problems, but the second group received no hormonal treatment. There was no evidence to suggest that Proluton-Depot had any adverse effect on the infant or the final outcome of pregnancy.

Topics

Pregnancy > Progesterone Supplementation > Hydroxyprogesterone Pregnancy > First Trimester > Threatened Miscarriage Treatment Reproductive Endocrinology > Progestogens > Clinical Safety

hydroxyprogesterone hexanoate early pregnancy outcome, Proluton Depot progesterone supplementation first trimester, intramuscular progesterone early pregnancy fetal safety, hydroxyprogesterone caproate threatened pregnancy treatment, Varma Morsman Proluton Depot pregnancy evaluation, progesterone support early pregnancy threatened abortion, hormonal treatment first trimester pregnancy outcome, progestogen supplementation fetal safety assessment, case-controlled progesterone treatment early gestation, injectable progesterone pregnancy maintenance fetal outcome

PMID 6126401 6126401 DOI 10.1016/0020-7292(82)90039-x 10.1016/0020-7292(82)90039-x

Cite this article

Varma, T. R., & Morsman, J. (1982). Evaluation of the use of Proluton-Depot (hydroxyprogesterone hexanoate) in early pregnancy. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 20(1), 13-17. https://doi.org/10.1016/0020-7292(82)90039-x

Keywords

17 alpha-Hydroxyprogesterone Caproate, Abnormalities, Drug-Induced/etiology, Abortion, Spontaneous/drug Therapy, Adult, Corpus Luteum Maintenance/drug Effects, Female, Humans, Hydroxyprogesterones/adverse Effects/therapeutic Use, Infant, Newborn, Infertility, Female/drug Therapy, Outcome and Process Assessment, Health Care, Pregnancy, Prenatal Exposure Delayed Effects, Hydroxyprogesterones, 17 alpha-Hydroxyprogesterone Caproate

General OB/GYNMedical TraumaAdverse EventsCross-Sectional Studies

Prevalence of medically induced psychological trauma and its influence on women's health

Krolak M et al., 2023Int J Gynaecol Obstet

The aim of the present study was three-fold. One, to assess the prevalence of medical traumatization in outpatients of a gynecologic department; two, to analyze the relationship of medical traumatization with adverse childhood events; and three, to investigate the extent to which medical traumatization affects the health outcomes of woman. Between January and September 2022, a prospective cross-sectional study recruited patients of a gynecologic outpatient clinic at St. Gallen Cantonal Hospital in Switzerland. Medical trauma was a self-reported item. The presence of adverse childhood events was assessed using the Childhood Trauma Questionnaire. The severity of post-traumatic stress was evaluated using the Impact of Event Scale Revised questionnaire. In total, 227 patients were recruited. Medical trauma was reported by 20% of the interviewees and it was strongly associated with obesity (A = 0.005). Undergoing surgery was most commonly the source of psychological distress (5.7%) followed by delivery (4.8%), pregnancy loss (4.8%), and cancer diagnosis (4.0%). Yet, fewer than 1% of the patients reached the threshold suggesting post-traumatic stress disorder. We found no relationship between the medical trauma, adverse childhood events, cardiovascular disease, or substance abuse. The presence of medical trauma was associated with the patient's body mass index (calculated as weight in kilograms divided by the square of height in meters).

PregnancyGeneral OB/GYN

Risk factors for anxiety and depression among pregnant women during the COVID-19 pandemic: Results of a web-based multinational cross-sectional study

Kajdy A et al., 2022Int J Gynaecol Obstet

To assess risk factors for anxiety and depression among pregnant women during the COVID-19 pandemic using Mind-COVID, a prospective cross-sectional study that compares outcomes in middle-income economies and high-income economies. A total of 7102 pregnant women from 12 high-income economies and nine middle-income economies were included. The web-based survey used two standardized instruments, General Anxiety Disorder-7 (GAD-7) and Patient Health Questionnaire-9 (PHQ-9). Pregnant women in high-income economies reported higher PHQ-9 (0.18 standard deviation [SD], P < 0.001) and GAD-7 (0.08 SD, P = 0.005) scores than those living in middle-income economies. Multivariate regression analysis showed that increasing PHQ-9 and GAD-7 scales were associated with mental health problems during pregnancy and the need for psychiatric treatment before pregnancy. PHQ-9 was associated with a feeling of burden related to restrictions in social distancing, and access to leisure activities. GAD-7 scores were associated with a pregnancy-related complication, fear of adverse outcomes in children related to COVID-19, and feeling of burden related to finances. According to this study, the imposed public health measures and hospital restrictions have left pregnant women more vulnerable during these difficult times. Adequate partner and family support during pregnancy and childbirth can be one of the most important protective factors against anxiety and depression, regardless of national economic status.

SurgeryIsthmocele RepairUterine Defect CorrectionScar Defect Management

Robot-assisted laparoscopy repair of uterine isthmocele: A two-center observational study

Cardaillac C et al., 2022Int J Gynaecol Obstet

To analyze outcomes and postoperative complications in patients undergoing robot-assisted isthmocele repair. This retrospective cohort study included 33 patients who had robot-assisted laparoscopic surgical management of an isthmocele between September 2013 and August 2020 in two French university hospitals. All charts were reviewed to identify patient characteristics, preoperative and postoperative anatomical findings, complications, and postoperative fertility and symptoms. Patients who had undergone this procedure were asked to complete a telephone questionnaire about their treatment satisfaction and symptoms. The isthmocele was discovered most often as a result of subfertility (57.6%), but also ectopic pregnancy (18.2%), pelvic pain (15.2%), and postmenstrual bleeding (9.1%). Robot-assisted repair of the isthmocele significantly improved myometrial thickness (from 1.55 mm before surgery to 4.26 mm after surgery [mean difference 2.71; 95% confidence interval, 1.91-3.51], P = 0.0005). Among 20 patients who still desired a child after surgery, 15 became pregnant and 14 had full-term live births. Among the nine patients who had surgery for disabling symptoms, five had no persistent symptoms, three reported global improvement, and one had the same gynecologic discomfort. Seventeen patients agreed to complete the questionnaires (51.5%), and all stated that they would choose to have this surgery again. Robot-assisted repair of an isthmocele is a viable minimally invasive procedure.

Contraception/ComparisonReproductive Endocrinology Open Access

Effects of three contraceptive methods on depression and sexual function: An ancillary study of the ECHO randomized trial

Singata-Madliki M et al., 2021Int J Gynaecol Obstet

To compare the effects of depot medroxyprogesterone acetate (DMPA-IM), levonorgestrel (LNG) implant, and copper intrauterine device (IUD) on mood and sexual function. At the Effective Care Research Unit in South Africa, women already randomized in the ECHO Trial to the three methods were asked to participate in this study. Participants were interviewed at 3 and 12 months after enrollment using the Beck Depression Inventory and Arizona Sexual Experiences Scale, and at 12 months using the WHO-5 Wellbeing Index and the Patient Global Impression scale. A total of 605 women participated. There was little difference in depression at 3 months across the three study groups. Contrary to our hypothesis, at 12 months, depression was lowest among DMPA-IM users (16/167, 9.6%) and highest among IUD users (28/158, 17.7%) (p = 0.032). There was little difference in sexual function at any time-point. More women in the DMPA-IM group felt "very much better" on the PGI scale than in the IUD and LNG implant groups (p = 0.003). Depression may be less likely with DMPA-IM than with the other methods 1 year after initiation. Major differences in sexual functioning are unlikely. Unhappiness related to not using DMPA-IM, the most popular method in our setting, may have skewed results. PACTR201706001651380.

Evaluation of the use of Proluton-Depot (hydroxyprogesterone hexanoate) in early pregnancy

Abstract

Topics

Cite this article

Keywords

Related articles

Prevalence of medically induced psychological trauma and its influence on women's health

Risk factors for anxiety and depression among pregnant women during the COVID-19 pandemic: Results of a web-based multinational cross-sectional study

Robot-assisted laparoscopy repair of uterine isthmocele: A two-center observational study

Effects of three contraceptive methods on depression and sexual function: An ancillary study of the ECHO randomized trial